Company
Clarity Pharmaceuticals Ltd
ASX:CU6
Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.
At a glance
- Listing
- ASX:CU6
- Category
- Diagnostics
- Headquarters
- Eveleigh, Sydney, NSW, Australia
- Market cap
- ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32)
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- 14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:CU6 |
| Secondary listing | None |
| Market cap | ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32) |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Eveleigh, Sydney, NSW, Australia
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Clarity Pharmaceuticals: Radiopharmaceutical Therapies and Imaging (HQ address and SAR Technology pipeline) · Clarity Pharmaceuticals
- Clarity Pharmaceuticals Ltd (ASX:CU6) Market Cap · StockAnalysis
- Co-PSMA trial achieves primary endpoint · Clarity Pharmaceuticals
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma · PR Newswire
Every entity profile on variis is sourced. Not investment advice.